Heart Failure With Preserved Ejection Fraction Clinical Trials in Kansas City, Missouri

4 studies are recruiting for heart failure with preserved ejection fraction in Kansas City, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

    Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigational Site-105, Kansas City, Missouri
    Locations
    3 in total
    Run by
    35Pharma Inc., a GSK company

    See if you can join NCT07123779 on ClinicalTrials.gov

  2. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Saint Luke's Hospital of Kansas City, Kansas City, Missouri
    Locations
    686 in total
    Run by
    Amgen

    See if you can join NCT07037459 on ClinicalTrials.gov

  3. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage
    Not phased
    Ages
    18 and older
    Site
    St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City, Missouri
    Locations
    67 in total
    Run by
    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

  4. A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

    This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

    Stage
    Phase 2
    Ages
    30 to 84
    Site
    Local Institution - 11, Kansas City, Missouri
    Locations
    28 in total
    Run by
    Edgewise Therapeutics, Inc.

    See if you can join NCT07795814 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.